Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» Keytruda
Keytruda
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
Motley Fool
cancer
cancer immunotherapies
Opdivo
Bristol-Myers Squibb
Keytruda
Merck
Yervoy
Flag link:
FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths
FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths
Endpoints
FDA
Roche
Keytruda
Tecentriq
clinical trials
Flag link:
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Motley Fool
AbbVie
Humira
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Biogen
aducanumab
Flag link:
Cancer patients know immuno-oncology and top drugs, but lack details: study
Cancer patients know immuno-oncology and top drugs, but lack details: study
Fierce Pharma
patients
cancer
immuno-oncology
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Flag link:
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals
Fierce Pharma
ESMO
Merck
Keytruda
bladder cancer
Flag link:
ESMO: Merck piles on the positive Keytruda-chemo combo results in lung cancer
ESMO: Merck piles on the positive Keytruda-chemo combo results in lung cancer
Fierce Pharma
Merck
Keytruda
ESMO
lung cancer
Flag link:
FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials
FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials
RAPS.org
FDA
Merck
Keytruda
Multiple Myeloma
Flag link:
Incyte’s good week continues with an encouraging update on IDO1 star epacadostat
Incyte’s good week continues with an encouraging update on IDO1 star epacadostat
Endpoints
Incyte
IDO1
epacadostat
Keytruda
Merck
Flag link:
Incyte, Merck build case for skin cancer combo
Incyte, Merck build case for skin cancer combo
BioPharma Dive
Incyte
Merck
Keytruda
advanced melanoma
Flag link:
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Motley Fool
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Flag link:
Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval
Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval
Fierce Pharma
Bristol-Myers Squibb
Opdivo
colorectal cancer
Merck
Keytruda
Flag link:
Keytruda keeps on climbing for Merck as other PD-1s flounder
Keytruda keeps on climbing for Merck as other PD-1s flounder
BioPharma Dive
Merck
Keytruda
Flag link:
The Startling History Behind Merck's New Cancer Blockbuster
The Startling History Behind Merck's New Cancer Blockbuster
Forbes
Merck
Keytruda
cancer
R&D
Organon
Flag link:
Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer
Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer
Xconomy
Merck
Keytruda
head and neck cancer
Flag link:
Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending
Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending
Fierce Pharma
Merck
Keytruda
drug pricing
non-small cell lung cancer
Flag link:
FDA Considers Label Changes for Keytruda, Opdivo and Yervoy
FDA Considers Label Changes for Keytruda, Opdivo and Yervoy
RAPS.org
FDA
labeling
Keytruda
Opdivo
Yervoy
immuno-oncology
Merck
Bristol-Myers Squibb
Flag link:
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
Motley Fool
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
AbbVie
JNJ
Imbruvica
Pfizer
Ibrance
cancer
Flag link:
What the FDA's Hold on Three Merck Studies Means for Other Drug Makers
What the FDA's Hold on Three Merck Studies Means for Other Drug Makers
TheStreet.com
Merck
Keytruda
FDA
clinical trials
Multiple Myeloma
Bristol-Myers Squibb
AstraZeneca
Celgene
Flag link:
Prescribed Reading: I/O is the only game in town
Prescribed Reading: I/O is the only game in town
BioPharma Dive
immuno-oncology
Celgene
BeiGene
Endo International
Opana ER
Novartis
Orkambi
Vertex Pharmaceuticals
Merck
Bristol-Myers Squibb
Roche
Opdivo
Keytruda
Orencia
Flag link:
Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies
Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies
Endpoints
FDA
Merck
Keytruda
clinical trials
Multiple Myeloma
Flag link:
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »